Predictors of this conversion include whether the patients are carriers of ε4 alleles of the apolipoprotein E (APOE) gene, brain atrophy, clinical severity, patterns of cerebrospinal fluid (CSF) biomarkers, cerebral glucose metabolism, and A(β) deposition [8,9]. This evidence concerns the gene APOE and Brain atrophy.